APG333
Respiratory & Broader I&I Conditions
Phase 1First participants dosed (Dec 2024)
Key Facts
Indication
Respiratory & Broader I&I Conditions
Phase
Phase 1
Status
First participants dosed (Dec 2024)
Company
About Apogee Therapeutics
Founded in 2022, Apogee Therapeutics aims to reshape the standard of care for inflammatory and immune diseases by developing potentially best-in-class biologics with optimized dosing intervals. Its pipeline includes monotherapies and rational combinations targeting validated pathways like IL-13, OX40L, and TSLP across dermatological, respiratory, and gastroenterological conditions. The company is publicly traded (NASDAQ: APGE) and is advancing multiple programs with key clinical readouts expected in 2026.
View full company profile